Curasight (CURAS) Q2 2026 earnings summary

Executive summary

• Focus on developing a uPAR-targeted theranostic platform for diagnosis and treatment of aggressive solid tumors, including glioblastoma, NSCLC, and others, with both diagnostic (uTRACE®) and therapeutic (uTREAT®) programs in clinical and preclinical trials.

• Achieved key clinical progress with encouraging preliminary Phase 1 data for uTREAT® in glioblastoma, marking a significant milestone for the platform.

• Recent internal ownership restructuring consolidated co-founders' holdings under Curacap II ApS, now holding 27.69% of shares, without affecting operations or strategy.

• Strengthened financial position through a DKK 20 million directed share issue and extension of a DKK 35 million convertible loan to mid-2027, supporting ongoing clinical programs.

• Updated clinical timelines: topline Phase I uTREAT® in glioblastoma and Phase II uTRACE® in prostate cancer expected H1 2027.

Financial highlights

• H1 2026 gross loss: KDKK -22,875 (vs. KDKK -22,399 year-over-year); operating loss: KDKK -26,771 (vs. KDKK -25,220); loss before tax: KDKK -29,505 (vs. KDKK -27,158); net loss: KDKK -26,755 (vs. KDKK -24,408).

• Q2 2026 gross loss: KDKK -9,797 (vs. KDKK -17,700); operating loss: KDKK -11,493 (vs. KDKK -19,011); loss before tax: KDKK -12,800 (vs. KDKK -20,579); net loss: KDKK -11,425 (vs. KDKK -19,204).

• Total assets: KDKK 56,081 (vs. KDKK 44,783); equity ratio: 27.1% (vs. 67.6%); EPS: DKK -0.24 (vs. DKK -0.43).

• Cash in hand as of June 30, 2026: KDKK 41,026 (vs. KDKK 29,449 year-over-year).

• Short-term debt: KDKK 40,868, mainly from a drawn credit facility.

Outlook and guidance

• Topline results for Phase I uTREAT® in glioblastoma and Phase II uTRACE® in prostate cancer expected H1 2027, with timelines reflecting patient enrollment uncertainties.

• Protocol amendment in Phase I uTREAT® trial aims to optimize study design and broaden data for next phase.

• Regulatory tailwind anticipated for glioblastoma program.

• Continued disciplined execution and robust clinical evidence generation are strategic priorities.